President Josipović Opens New State-of-the-Art R&D Facilities at PLIVA
New R&D Laboratories for Complex Molecules and New Therapeutic Entities • Investments in R&D of medicinal products total HRK 250 million in 2014 • New jobs for young and highly educated experts and scientists
Zagreb, 1 December 2014 –The President of the Republic of Croatia Dr. Ivo Josipović officially opened new R&D facilities for complex molecules and new therapeutic entities at PLIVA's Research Institute.
The official opening was attended by renowned members of professional and scientific communities who made a tour of the new cutting-edge laboratories and attended presentations on future challenges in the pharmaceutical industry.
In 2014, R&D investments at PLIVA totalled HRK 250 million and created jobs for 30 people. In line with the company's systematic investments in new technologies, the Zagreb Centre of Excellence has remained one of the key R&D centres of the Teva Group, of which PLIVA is a member.
“I am exceptionally proud that Teva has recognised PLIVA, and therefore Croatia and its people, as a guarantee for its further successful operations. Our latest investment in new laboratories and state-of-the art equipment resulted in opening of additional jobs and employment of new scientists and other experts. Over the last three years we have employed 70 new talents in research and development, and we are continuously investing in their further education to enable them to successfully respond to current and future challenges in the healthcare industry”, said Tihomir Orešković, President of PLIVA’s Management Board, and added: “Investing in science, and in our case in research and development of complex molecules and new therapeutic entities, is of utmost importance and provides a solid platform for progress and evolution of the overall Croatian economy and for strengthening of our links with scientific institutions.“
When talking about Teva and the future of the pharmaceutical industry, Dr. Michael Hayden, President of Teva’s Global R&D and Chief Scientific Officer, said: “I appreciate PLIVA’s rich history and tradition, and superior results of its scientists. Teva’s investment in PLIVA shows that Croatia has both capabilities and expertise to successfully compete on the most demanding global markets and to achieve enviable results. Our R&D Center in Zagreb is the largest pharmaceutical R&D center in Croatia and the 3rd largest in Teva’s R&D network. The people we employ in Zagreb know they are not just part of a local operation. They are right at the heart of something much bigger. They are driving highly complex projects, requiring intimate knowledge of international regulatory requirements and working hand-in-hand with a truly global team. This enables us to meet the needs of our patients worldwide.“
Katica Lazarić, Senior Director, Generic R&D Zagreb, talked about PLIVA’s R&D investments, which considerably exceed average figures in Croatia, and said: “The additional investment in state-of-the-art equipment, which enables us to develop complex solutions that will one day result in concrete medicinal products, is great news for any scientist or expert. We believe that new therapeutic options will improve the quality of life of our patients and help their families and healthcare providers. We are proud to be given this opportunity to successfully work here in Croatia and to be present with our achievements in a number of global markets”, emphasised Katica Lazarić.
The year 2014 has been also one of the most successful years in PLIVA’s almost hundred year old history. One of the largest investment cycles in the company’s history, totalling over USD 200 million has been completed this year and it has significantly increased the company’s manufacturing capacities, with more than 80% of products exported to the most demanding pharmaceutical markets.